Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro

3Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Bufalin (buf) has poor solubility in aqueous solution, poor tumor targeting, and many non-specific toxic and side effects. The advantages of high-molecular-weight polymer conjugates are that they can improve the water solubility of buf, prolong plasma half-life, and reduce non-specific toxicity. A novel water-soluble polymer–drug conjugate with buf and fluorescein pendants was prepared by the combination of reversible addition-fragmentation transfer (RAFT) polymerization and click chemistry. Its anticancer performance and cellular uptake behavior against liver cancer were investigated in vitro. The polymer–buf conjugates exhibit controlled release and tumor-targeting capabilities, showing promise for clinical applications.

Cite

CITATION STYLE

APA

Xu, J., Lin, S., Hu, H., Xing, Q., & Geng, J. (2022). Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro. Polymers, 14(21). https://doi.org/10.3390/polym14214515

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free